Literature DB >> 17113348

Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.

Zeyu Xiong1, Yan Yan, Enli Liu, Richard T Silver, Srdan Verstovsek, Fan Yang, Hong Wang, Josef Prchal, Xiao-Feng Yang.   

Abstract

We attempted to determine whether the immune reactions elicited by aberrantly expressed testis antigens contribute to the beneficial responses to interferon (IFN)-alpha therapy and other therapies in patients with polycythemia vera (PV). We screened a human testis cDNA library using SEREX (serological analysis of tumor antigens by screening an expression cDNA library with sera from three patients with PV who had undergone IFN-alpha-induced or other therapeutics-induced remission). We identified two novel PV associated tumor antigens, PV65 (eIF-2alpha) and PV13 (protamine 2). These 2 antigens elicited IgG antibody reactions in a subset of PV patients but not in healthy donors, suggesting that they are authentic tumor antigens. Increased phosphorylation of PV65 in response to stimulation of IFN-alpha, and upregulation of PV13 in tumor cells might enhance their abilities in elicitation of immune reactions in patients. These findings provide new insights into the mechanism underlying the regulation of the self-antigen repertoire in eliciting anti-tumor immune reactions in patients with polycythemia vera, and suggest their potential as the targets of novel immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113348      PMCID: PMC2637448          DOI: 10.1016/j.clim.2006.10.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  50 in total

Review 1.  Current management in polycythemia vera.

Authors:  H S Gilbert
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

2.  Protamine-1 and -2 mRNA in round spermatids is associated with RNA-binding proteins.

Authors:  Klaus Steger; Ludger Fink; Thomas Klonisch; Rainer M Bohle; Martin Bergmann
Journal:  Histochem Cell Biol       Date:  2002-02-08       Impact factor: 4.304

Review 3.  Interferon alpha in the treatment of polycythemia vera.

Authors:  E Lengfelder; U Berger; R Hehlmann
Journal:  Ann Hematol       Date:  2000-03       Impact factor: 3.673

4.  CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.

Authors:  X F Yang; C J Wu; S McLaughlin; A Chillemi; K S Wang; C Canning; E P Alyea; P Kantoff; R J Soiffer; G Dranoff; J Ritz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

5.  Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.

Authors:  C J Wu; X F Yang; S McLaughlin; D Neuberg; C Canning; B Stein; E P Alyea; R J Soiffer; G Dranoff; J Ritz
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

6.  Characterization of a novel gene, STAG1/PMEPA1, upregulated in renal cell carcinoma and other solid tumors.

Authors:  F K Rae; J D Hooper; D L Nicol; J A Clements
Journal:  Mol Carcinog       Date:  2001-09       Impact factor: 4.784

Review 7.  Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.

Authors:  M Bhattachary-Chatterjee; R Nath Baral; S K Chatterjee; R Das; H Zeytin; M Chakraborty; K A Foon
Journal:  Cancer Immunol Immunother       Date:  2000-06       Impact factor: 6.968

8.  HLA-A2.1-restricted T cells react to SEREX-defined tumor antigen CML66L and are suppressed by CD4+CD25+ regulatory T cells.

Authors:  Y Yan; Y Chen; F Yang; I H Chen; Z Xiong; J Wang; L B Lachman; H Wang; X-F Yang
Journal:  Int J Immunopathol Pharmacol       Date:  2007 Jan-Mar       Impact factor: 3.219

Review 9.  Death, autoantigen modifications, and tolerance.

Authors:  P J Utz; T J Gensler; P Anderson
Journal:  Arthritis Res       Date:  2000-02-09

Review 10.  Challenges to the development of antigen-specific breast cancer vaccines.

Authors:  M J Scanlan; D Jäger
Journal:  Breast Cancer Res       Date:  2001-01-11       Impact factor: 6.466

View more
  12 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

2.  Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors.

Authors:  Swarna Mehrotra; Bhumika Sharma; Sonali Joshi; Barbara Kroczynska; Beata Majchrzak; Brady L Stein; Brandon McMahon; Jessica K Altman; Jonathan D Licht; Darren P Baker; Elizabeth A Eklund; Amittha Wickrema; Amit Verma; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

3.  The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.

Authors:  M O Holmström; M D Hjortsø; S M Ahmad; Ö Met; E Martinenaite; C Riley; P Straten; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2016-10-20       Impact factor: 11.528

4.  Myelofibrosis 2012: it's complicated.

Authors:  Harper G Hubbeling; Dale M Frank; Elizabeth O Hexner
Journal:  Ther Adv Hematol       Date:  2012-06

Review 5.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

6.  Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.

Authors:  Min Lu; Wei Zhang; Yan Li; Dmitriy Berenzon; Xiaoli Wang; Jiapeng Wang; John Mascarenhas; Mingjiang Xu; Ronald Hoffman
Journal:  Exp Hematol       Date:  2010-03-18       Impact factor: 3.084

Review 7.  Running interferon interference in treating PV/ET: meeting unmet needs.

Authors:  Elizabeth A Traxler; Elizabeth O Hexner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

8.  Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Taghi Manshouri; Rajyalakshmi Luthra; Zeev Estrov; Sherry Pierce; Mary Ann Richie; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

9.  The Role of Immunogenicity in Cardiovascular Disease.

Authors:  Michael Jan; Anthony T Virtue; Meghanaben Pansuria; Jingshan Liu; Xinyu Xiong; Pu Fang; Shu Meng; Hong Wang; Xiao-Feng Yang
Journal:  World Heart J       Date:  2011-01-01

10.  Canonical Secretomes, Innate Immune Caspase-1-, 4/11-Gasdermin D Non-Canonical Secretomes and Exosomes May Contribute to Maintain Treg-Ness for Treg Immunosuppression, Tissue Repair and Modulate Anti-Tumor Immunity via ROS Pathways.

Authors:  Dong Ni; TingTing Tang; Yifan Lu; Keman Xu; Ying Shao; Fatma Saaoud; Jason Saredy; Lu Liu; Charles Drummer; Yu Sun; Wenhui Hu; Jahaira Lopez-Pastrana; Jin J Luo; Xiaohua Jiang; Eric T Choi; Hong Wang; Xiaofeng Yang
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.